Cost-effectiveness Analysis on Five Regimens of Antibacterial Drug Therapy in the Treatment of Community Acquired Pneumonia
- VernacularTitle:5种抗菌药物治疗方案治疗社区获得性肺炎的成本-效果分析
- Author:
Zhilin HU
;
Xi PENG
- Publication Type:Journal Article
- Keywords:
Community acquired pneumonia;
Regimes of antibacterial drug therapy;
Cost-effectiveness analysis
- From:
China Pharmacy
1991;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To evaluate the cost-effectiveness of five regimens of antibacterial drug therapy in the treatment of community acquired pneumonia. METHODS: A retrospective study was conducted, in which a total of 128 cases with pneumonia were enrolled and randomly assigned to receive each of the following 5 therapies,cefoperazone sodium/ sulbactam sodium(Group A),levofloxacin(Group B),amoxicillin/ clavulanate potassium(Group C),azithromycin plus ceftazidime(Group D),and cefoxitin(Group E),the therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the five groups. RESULTS: The costs of the five regimens were 2 137.0 yuan, 1 393.0 yuan, 1 152.5yuan, 2 044.2 yuan and 1 827.0 yuan, respectively;The effective rates were 85.2%, 86.6%, 80.6%, 89.6% and 78.5%, respectively;The cost-effectiveness ratios were 25.08 , 16.09, 14.30, 22.82 and 23.27, respectively; As compared with group C, the incremental cost-effectiveness ratios of the other four groups were 214.02,40.08, 99.08 and —321.19, respectively. CONCLUSION: The therapy of amoxicillin/ potassium clavulanate is superior to the other regimes in the treatment of community acquired pneumonia.
